ArticleAntiviral research2014
What are the pros and cons of the use of host-targeted agents against hepatitis C?
Article in Antiviral research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Sulfonyl Anthranilic Acid Analogues Display Pan-Serotype Anti-Dengue Activity by Downregulating the Expression of Ribosomal Proteins Encoded by 5'-Terminal Oligopyrimidine Motif-Containing mRNA.Journal of medicinal chemistry · 2026Article
- Novel Pyrazino[1,2-Viruses · 2024Article
- A pan-respiratory antiviral chemotype targeting a transient host multi-protein complex.Open biology · 2024Article
- A Pan-Respiratory Antiviral Chemotype Targeting a Host Multi-Protein Complex.bioRxiv : the preprint server for biology · 2023Article
- Recent Updates on Viral Oncogenesis: Available Preventive and Therapeutic Entities.Molecular pharmaceutics · 2023Review
- Targeting Human Proteins for Antiviral Drug Discovery and Repurposing Efforts: A Focus on Protein Kinases.Viruses · 2023Review
- Antiviral strategies targeting host factors and mechanisms obliging +ssRNA viral pathogens.Bioorganic & medicinal chemistry · 2021Review
- Anti-Hepatitis C Virus Activity of Uridine Derivatives of 2-Deoxy Sugars.Molecules (Basel, Switzerland) · 2018Article
- Hepatitis: MicroRNA antagonists: promising antiviral agents against HCV and other viruses?Nature reviews. Gastroenterology & hepatology · 2017Article
- Rad51 Interacts with Non-structural 3 Protein of Hepatitis C Virus and Regulates Viral Production.Frontiers in microbiology · 2017Article
- A Sequence in the loop domain of hepatitis C virus E2 protein identified in silico as crucial for the selective binding to human CD81.PloS one · 2017Article
- Hepatitis C treatment: where are we now?International journal of general medicine · 2017Review
- New prospects for the treatment and prevention of hepatitis C in children.Current opinion in pediatrics · 2016Review
- Review
- Hepatitis C virus: Virology, diagnosis and treatment.World journal of hepatology · 2015Review
- Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus.Journal of virology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) therapy is living a revolution. Host-targeted agents (HTAs) block HCV production by interacting with host cell components. Because they target conserved host proteins, not variable viral proteins, HTAs have the potential for pangenotypic antiviral activity and a high barrier to resistance. Only two HTAs have reached clinical development, including specific inhibitors of cyclophilin A peptidyl-prolyl cis/trans isomerase activity and antagonists of microRNA-122. Cyclophilin inhibitors have proven to be relatively well tolerated and can be confidently used as backbones of all-oral, interferon-free regimens. In addition, HTAs such as cyclophilin inhibitors offer opportunities for "panviral" approaches when they target mechanisms common to viruses of the same or different families. This article forms part of a symposium in Antiviral Research on "Hepatitis C: next steps toward global eradication."
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.